TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 6, 2014, Pages

  Liu, Xiaoli ^a   Qu, Shen ^b   Liu, Rengyun ^a   Sheng, Chunjun ^b   Shi, Xiaoguang ^a   Zhu, Guangwu ^a   Murugan, Avaniyapuram Kannan ^a   Guan, Haixia ^c   Yu, Hongyu ^d   Wang, Yangang ^e   Sun, Hui ^f   Shan, Zhongyan ^c   Teng, Weiping ^c   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e QINGDAO UNIVERSITY   (China)

^f JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; IODINE;

ADULT; ADVANCED CANCER; AGE; ARTICLE; BENIGN TUMOR; BRAF GENE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CARCINOMA; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE; THYROID NEOPLASMS; VALINE;

EID: 84902303028     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4048     Document Type: Article

References (27)

1. Smekalova EM, Shubernetskaya OS, Zvereva MI, Gromenko EV, Rubtsova MP, Dontsova OA. Telomerase RNA biosynthesis and processin g. Biochemistry (Mosc). 2012;77:1120-1128.
2. Mocellin S, Pooley KA, Nitti D. Telomerase and the search for the end of cancer. Trends Mol Med. 2013;19:125-133.
3. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611-622.
4. González-Su árez E, Samper E, Ramírez A, et al. Increased epidermal tum ors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 2001;20:2619-2630.
5. González-Su árez E, Flores JM, Blasc o MA. Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol Cell Biol. 2002;22:7291-7301.
6. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959-961.
7. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957-959.
8. Liu X,WuG, Shan Y, Hartmann C, von Deimling A, XingM.Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12:1637-1638.
9. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. P roc Natl Acad Sci USA. 2013;110: 6021-6026.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
11. Howlader N, Noone AM, Krapcho M, et al. 2013 SEER Cancer Statistics Review, 1975-2010. National Cancer Institute. http://seer.cancer.gov/csr/1975- 2010/. Published June 12, 2013. Accessed January 10, 2014.
12. DeLellis RA, Lloyd RV, Heitz PU. Pathology and Genetics: Tumours of Endocrine Organs.WHOClassification of Tumors. Lyon, France: IARC Press; 2004.
13. Xing M: BRAF mutation in thyroid cancer Endocr Relat Cancer. 2005 12 245-262.
14. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28:742-762.
15. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603-610.
16. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612-1617.
17. Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98:E1562-E1566.
18. Vina gre J, Almeida A, Pópulo H, et al. Frequency ofTERTpromoter mutations in human cancers. Nat Commun. 2013;4:2185.
19. Liu T, Wang N, Cao J, et al. The age-and shorter telomere-de pendent TERT promoter mutation in follicular thyroid cell-derived carcinomas [published online October 21, 2013]. Oncogene. doi: 10.1038/onc.2013.446.
20. Dal Maso L, Bosetti C, La Vecchia C, Franceschi S . Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control. 2009;20:75-86.
21. Knobel M, Medeiros-Neto G. Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. Arq Bras Endocrinol Metabol. 2007;51:701-712.
22. Janknecht R, Ernst WH, Nordheim A. SAP1a is a nuclear target of signaling cascades involving ERKs. Oncogene. 1995;10:1209-1216.
23. Strahl T, Gille H, Shaw PE. Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups. Proc Natl Acad Sci USA. 199 6;93:11563-11568.
24. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science. 1995;269:403-407.
25. Xing M, Liu X, Liu R, Pai SI, Zeiger M, Bishop J. TERT promoter mutation corporates with BRAF mutation to promote thyroid cancer recurrence. In: Proceedings from the American Thyroid Association; October 16-20, 2013; San Juan, Puerto Rico.
26. Nucera C, Porrello A, Antonello ZA, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA. 2010;107:10649-10654.
27. Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 2011;71:2417-2422.